Recro Pharma, Inc.
Nanoparticulate Meloxicam Formulations
Last updated:
Abstract:
The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm.
Status:
Application
Type:
Utility
Filling date:
25 Aug 2019
Issue date:
19 Dec 2019